Secukinumab in multi-failure psoriatic patients: the last hope?

Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic...

Full description

Saved in:
Bibliographic Details
Published inJournal of Dermatological Treatment Vol. 29; no. 6; pp. 583 - 585
Main Authors Magnano, M., Loi, C., Patrizi, A., Sgubbi, P., Balestri, R., Rech, G., Tasin, L, Girardelli, C. R., Conti, A., Odorici, G., Campanati, A., Offidani, A. M., Bardazzi, F.
Format Report
LanguageEnglish
Published Taylor & Francis 18.08.2018
Subjects
multi-failure
Psoriasis
secukinumab
Online AccessGet full text

Cover

More Information
Summary:Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also these agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a human monoclonal antibody that selectively neutralizes interleukin-17 A and is recently approved for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
ISSN:0954-6634
1471-1753
DOI:10.1080/09546634.2018.1427206